SecBot SecBot

MRKR drug pipeline

$0.8300
−4.6% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 mixed
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 2
Time to marketUnknown — MT-601 is in Phase 2 for lymphoma (APOLLO study) and preparing a Phase 1 pancreatic cancer study (expected Q1 2027). A registrational trial has not yet begun. At minimum 3-5 years away from potential approval, if ever.

MT-601 Updated Oct 24

What to watch

Watch for the Phase 1 pancreatic cancer study initiation in Q1 2027 and the upcoming Q3 2026 earnings (Nov 11). The critical near-term risk is the company's cash runway, with ~$17M at year-end 2025 and a $12M+ annual burn, MRKR likely needs to raise capital within months, which would dilute existing shareholders. The massive analyst price target spread ($5.60-$10 vs $0.96 stock) suggests genuine clinical promise but extreme execution risk at current funding levels.

Bull case
  • MT-601 showed compelling early efficacy: 66% objective response rate (8/12 evaluable patients) including 50% complete responses in relapsed/refractory non-Hodgkin lymphoma from the APOLLO study, and 78% ORR in Hodgkin lymphoma.
  • Pancreatic cancer data published in Nature Medicine showed 84.6% disease control rate and 14.1-month median overall survival when MT-601 was combined with chemotherapy in a prior Baylor investigator-sponsored study.
  • FDA awarded a competitive $2.6M Orphan Products Clinical Trials Grant (only 6 of 66 applications funded in FY2026) for the MT-601 pancreatic cancer program, a strong external validation of the scientific rationale.
Bear case
  • Cash runway is tight, $17M at year-end 2025 funded only through Q4 2026, and with a ~$12M annual operating burn the company likely needs to raise capital imminently. Stock is already near its 52-week low of $0.84, and a proposed 4.3x increase in authorized shares (from 30M to 130M) signals significant shareholder dilution ahead.
  • The clinical data comes from very small cohorts (8-12 patients per indication). Historical 66% ORR in the APOLLO lymphoma study and 84.6% disease control rate in pancreatic cancer may not replicate in larger, controlled trials.
  • Pancreatic cancer is an extremely difficult indication with a long history of failed therapies. The Phase 1 study has not yet started enrollment (expected Q1 2027) and faces high technical risk.